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Abstract: Pivotal brain functions, such as neurotransmission, cognition, and memory, decline with advancing age and, 
especially, in neurodegenerative conditions associated with aging, such as Alzheimer’s disease (AD). Yet, deterioration in 
structure and function of the nervous system during aging or in AD is not uniform throughout the brain. Selective neu-
ronal vulnerability (SNV) is a general but sometimes overlooked characteristic of brain aging and AD. There is little 
known at the molecular level to account for the phenomenon of SNV. Functional genomic analyses, through unbiased 
whole genome expression studies, could lead to new insights into a complex process such as SNV. Genomic data gener-
ated using both human brain tissue and brains from animal models of aging and AD were analyzed in this review. Con-
vergent trends that have emerged from these data sets were considered in identifying possible molecular and cellular 
pathways involved in SNV. It appears that during normal brain aging and in AD, neurons vulnerable to injury or cell 
death are characterized by significant decreases in the expression of genes related to mitochondrial metabolism and energy 
production. In AD, vulnerable neurons also exhibit down-regulation of genes related to synaptic neurotransmission and 
vesicular transport, cytoskeletal structure and function, and neurotrophic factor activity. A prominent category of genes 
that are up-regulated in AD are those related to inflammatory response and some components of calcium signaling. These 
genomic differences between sensitive and resistant neurons can now be used to explore the molecular underpinnings of 
previously suggested mechanisms of cell injury in aging and AD.  
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1. INTRODUCTION 
 Brain aging and associated neurodegenerative diseases 
such as Alzheimer’s disease (AD), do not affect all neurons 
equally. For example, in the hippocampus, neurons in the 
CA1 region are vulnerable to brain aging and AD, but those 
in the nearby CA3 region are not nearly as heavily damaged 
as the CA1 neurons [1-3]. A pattern of selective loss of syn-
apses and neurons in certain brain regions has been described 
for both the aging process [4-6] and AD [7-10]. These stud-
ies have been performed, for the most part, at the micro-
anatomical level and have identified relatively few neuro-
chemical changes that correlate with either neuronal vulner-
ability or resistance to age- or AD-associated injury or death. 
The selective vulnerability of certain brain neurons appears 
to be an intrinsic characteristic of these neurons. Besides 
aging and AD, this phenomenon, of selective neuronal vul-
nerability (SNV), is also a characteristic of many other neu-
ral insults, such as Parkinson’s disease [11], amyotrophic 
lateral sclerosis (ALS) [12], ischemia [13], epileptic seizures 
[14], and oxidative stress (OS) [15, 16]. Yet, SNV is often 
overlooked in the study of brain aging and neurodegenera-
tive diseases. By definition, SNV refers to the fact that, only 
select populations of neurons are uniquely vulnerable to 
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injury or death under adverse conditions, whereas other neu-
rons are relatively resistant to such stresses in their environ-
ment. The selective vulnerability of some neurons is often 
manifested in structural and functional changes that may or 
may not lead to the death of the cells. For example, vulner-
able neurons often suffer loss of dendrites that leads to a 
significant impairment of synaptic transmission, but the cells 
may still survive for a time in this altered state. Understand-
ing the mechanisms underlying SNV is an essential step in 
efforts to develop strategies to moderate the deleterious im-
pact of aging and neurodegenerative diseases on the overall 
quality of life.  
 The aging process and age-associated disease conditions, 
including AD, are marked by genomic instability and conse-
quential or compensatory changes in gene expression pat-
terns [17-19]. Since the functional status of cells is deter-
mined to a large extent by their genomic activity, genomic 
studies of neurons that are selectively vulnerable to brain 
aging and AD, are expected to yield new insights into the 
intrinsic biochemical and cell biological processes that make 
some neurons susceptible to a wide variety of stresses. In 
this review, we first describe the brain regions and/or neu-
ronal populations that are currently known to be most af-
fected by aging and AD. Secondly, we collect and carry out 
an analysis of the published functional genomic studies on 
the phenomenon of SNV in brain aging and AD. Finally, we 
attempt to integrate and discuss the findings from multiple 
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studies into some common patterns or characteristics that 
seem to offer the most likely explanations for the differential 
vulnerability of neuronal populations to stresses due to both 
aging and to disease. 
2. SELECTIVE NEURONAL VULNERABILITY IN 
BRAIN AGING  
2.1. Brain Regions that are Vulnerable to Normal Aging 
 As indicated above, several brain regions uniquely sus-
ceptible to age-dependent cell damage ultimately disrupt 
normal function and compromise behavioral performance. 
The frontal cortex is one such region that plays a pivotal role 
in cognition and memory, and even subtle changes in the 
neuronal environment of selectively vulnerable neurons ap-
pear to lead to the cognitive impairment characteristic of 
normal brain aging [20, 21]. In efforts to identify the most 
age-sensitive regions in the brain, non-invasive techniques 
such as structural brain imaging and functional magnetic 
resonance imaging are being widely used and combined with 
knowledge derived from post-mortem analyses of aging hu-
man brain. These studies, based mostly on volumetric meas-
urements in human brain, show that the association cortex, 
the neostriatum, and the cerebellum are the most vulnerable 
regions to age-dependent loss of volume, whereas the pri-
mary sensory cortices (such as the visual cortex), the en-
torhinal cortex, the paleostriatum, and the pons show much 
less shrinkage [22, 23]. (See Fig. (1) for location of several 
of these brain regions).  
 It is important to note that there are variable patterns in 
different brain regions with regard to volumetric changes 
during aging, or even during development. For example, the 
cerebellum does not change in volume from middle to old 
age. However, significant cerebellar volume decreases occur 
between young adulthood and middle age, with much less 
change taking place between middle and old age. Thus the 
volume shrinkage of the cerebellum occurs early in life and 
then slows down in the mid-50’s in humans [24]. In addition, 
it has been observed that during development, some cortical 
regions exhibit a continuous increase in volume, whereas in 
the frontal and parietal cortices the increase is followed by a 
decrease in volume during the transition from adolescence to 
young adulthood [25]. These changes in brain structure are 
not accompanied, of course, by cognitive decline in young 
individuals thus revealing the complexity faced with trying 
to link brain imaging changes and the cause of alterations in 
neurological function. Other indices of brain activity besides 
volume changes, such as positron emission tomography 
(PET) of cerebral metabolic rate of glucose (CMRGl), might 
provide additional correlative measures of structure to func-
tion in the human brain. 
 The brain volumetric measurements as well as the PET 
measures of CMRGl reinforce the notion that aging affects 
some regions of the brain more than others. In addition to the 
volume changes in select brain regions of the brain during 
aging, it has been repeatedly shown that the frontal cortex 
shows the greatest and most consistent decrements in CMRGl 
as compared with all other regions in the cortex or subcorti-
cal components of the aging brain [26, 27]. These changes in 
metabolic activity in select cortical areas during aging are 
either related to altered neuronal expression of some key 
enzymes controlling the overall metabolic state of neurons 
and associated glial cells, or they are the result of altered 
activation of synapses or of the disruptive effects of abnor-
mal neuronal excitability during aging. Gene expression 
analyses, in combination with neuro-imaging studies (includ-
ing PET scan), as well as detailed microanatomical investi-
gations, are providing new windows onto the molecular and 
cellular changes that might account for such differential pat-
terns of neuronal susceptibility to the aging process and to 
age-related diseases. It should be emphasized, however, that 
neuronal losses during aging even in select, sensitive regions 
are relatively modest, whereas decreases in the number of 
synapses in the same regions appear to be a more prominent 
characteristic of brain aging. These observations have led to 
the assertion that most of the functional decline associated 
with normal aging is caused by relatively subtle changes, 
such as loss of dendrites, reductions in spine densities, al-
tered spine morphologies, or changes in the molecular pro-
file of synapses [21, 28-31].  
2.2. Functional Genomic Studies on Brain Regions Most 
Vulnerable to Aging  
2.2.1. Human Studies 
 In order to study how brain regions differentially respond 
to the stresses associated with increasing age, some investi-
gators have used functional genomics approaches, though the 
number of these studies is still rather limited. Nevertheless, 









Fig. (1). Human brain structures examined in this review. Different views are shown in three panels: (A) lateral view of the left hemisphere, 
(B) medial view of the right hemisphere, and (C) sagittal view of one hemisphere. (The image in Panel C is adapted with permission from 
http://www.brains.rad.msu.edu, supported by the US National Science Foundation). 
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regional heterogeneity with respect to the differential rates of 
aging-associated changes. An initial report of differential 
gene expression patterns in three human brain regions was 
that by Evans et al. [32] who examined gene expression in 
cerebellar cortex and two cerebral cortical regions (anterior 
cingulate cortex and dorsolateral prefrontal cortex). The mi-
croarray gene expression patterns show that the two regions 
of the cerebral cortex had similar levels of expression of 
most genes and that these two cortical regions differed sig-
nificantly in terms of gene expression patterns from those of 
the cerebellar cortex [32]. More than one thousand tran-
scripts were differentially expressed in the cortical vs. cere-
bellar regions and the most prominent ontological categories 
among the differentially expressed genes were those of sig-
nal transduction, neurogenesis, synaptic transmission, and 
transcription factor regulation. In another study of regional 
differences in gene expression in human brain, Khaitovich et 
al. [33] analyzed patterns of expression in six areas of the 
brain: cerebellum, caudate nucleus, dorsolateral prefrontal 
cortex, anterior cingulate cortex, primary visual cortex, and 
Broca’s area. Consistent with the study by Evans et al. [32], 
Khaitovich et al. also found that while the four regions of the 
cerebral cortex are similar to each other, the overall tran-
scriptomic profiles of the cerebral cortex, the caudate nu-
cleus and the cerebellum differ significantly from each other 
[33]. The gene ontology categories that differed most in 
terms of expression in the various brain regions were those 
of synaptic transmission, signal transduction, neurogenesis, 
neuronal development, and calcium ion [Ca
2+
] regulation. 
Because the analyses of gene expression patterns in both the 
Evans et al. and Khaitovich et al. studies contained too few 
brain samples across the aging spectrum (45 to 88 years of 
age), Fraser et al. [34] conducted a meta-analysis on the re-
sults of these two studies using the aging-related pattern of 
changes in gene expression in the frontal pole of the human 
brain identified in the study by Lu et al. [18]. Using the 841 
genes identified as showing a pattern of either increasing or 
decreasing expression with advancing age in the Lu et al. 
study, they calculated the correlation coefficients resulting 
from comparisons of aging-related profiles between two tis-
sues (Spearman rank correlation, r, and significance P val-
ues), the frontal pole of the Lu et al. study and one of the 
tissues studied by Khaitovich et al. The investigators de-
scribed a highly significant correlation between the frontal 
pole in the Lu et al. study and each of the four regions of the 
cerebral cortex in the Khaitovich et al. study (anterior cingu-
late cortex, Broca’s area, prefrontal cortex, and primary vis-
ual cortex, r>0.8 and p<0.02), but a lack of correlation be-
tween the frontal pole and the two non-cerebral-cortical re-
gions (caudate nucleus and cerebellum, r<0.1 and p>0.4) in 
the Khaitovich et al. study. The meta-analysis confirmed the 
heterogeneity in age-dependent genome-wide gene expres-
sion profiles across different brain regions and demonstrated 
that the expression patterns of the five cerebral cortical re-
gions are quite similar to each other in terms of the rates of 
appearance of age-related changes, whereas the cerebellum 
and caudate nucleus respond to aging very differently. Fur-
ther analyses of the difference between the cerebral cortical 
regions and cerebellum revealed that the number of genes 
whose expression pattern changes with advancing age is 
lowest in the cerebellum.  
 A more recent study traced gene expression changes in 
four regions of postmortem brains in 55 normal individuals 
aged 20-99 years [35]. Similar to the studies described 
above, GeneChip data from this study again showed the re-
gional heterogeneity in gene expression patterns in human 
brain during the aging process. However, unlike previous 
studies that reported significantly higher numbers of genes 
whose expression was changing with advancing age in vul-
nerable brain regions as compared with less vulnerable re-
gions, this study indicated that two regions that are vulner-
able to aging and AD, the hippocampus and the entorhinal 
cortex, displayed fewer aging-responsive genes than the su-
perior frontal gyrus and post-central gyrus, regions that are 
less vulnerable to age-associated neuronal loss. It is impor-
tant to note, however, that the relative differences in age-
related neuronal injury or loss in these neocortical and paleo-
cortical regions are less pronounced than the differences be-
tween, for example, cerebral, cortical and cerebellar regions. 
Therefore, the results of the study by Berchtold et al. [35] 
may have identified more subtle differences among generally 
vulnerable brain regions.  
 Principal component analysis of gene expression in sin-
gle neurons captured by laser capture microdissection 
(LCM) from the two vulnerable regions of hippocampus and 
entorhinal cortex revealed that these neurons expressed 102 
genes at lower levels than did neurons in regions that are less 
susceptible to the aging process, such as the superior frontal 
gyrus and posterior cingulated cortex [36]. Beyond the fact 
that the results from this study confirm the differential pat-
tern of gene expression across several brain regions, they 
also point to some specific genes whose relatively low level 
of expression in susceptible regions in the aged brain (mean 
age: 79.8 ± 9.1 years) may predispose these neurons to dif-
ferential vulnerability to age and AD-associated injury and 
death. Among the top categories of genes that were under-
expressed in neuronal populations in the hippocampus and 
entorhinal cortex were those related to Ca
2+
 homeostasis, 
such as Slc8A1 (solute carrier family 8—sodium/calcium 
exchanger—member 1), Ppp2ca (protein phosphatase 2, 
catalytic subunit,  isoform) and Calm2 (calmodulin 2), and 
those associated with intracellular signaling. 
2.2.2. Animal Studies 
 As described above, the aging process is associated with 
specific gene expression patterns in the human brain but the 
genes expressed differentially in other species during the 
aging process differ from those detected in human brain even 
among close relatives of humans, such as the chimpanzee 
[34]. Despite the differences in specific gene expression pat-
terns among various species, neurons in certain brain re-
gions, such as the hippocampus CA1 field and the basal 
forebrain cholinergic neuronal region, are selectively vulner-
able in all species [16, 37-41]. Using a rodent model of brain 
aging, Xu et al. [42] studied five central nervous system re-
gions (cerebral cortex, hippocampus, striatum, cerebellum 
and spinal cord) across three age groups, 6 (young), 16 
(middle age), and 24 (old) month old animals. Each of these 
regions was shown to have a unique transcriptomic signa-
ture. Spinal cord has the most genes whose expression 
changes as a result of aging (600+), the cerebral cortex and 
hippocampus are next (each with 400+ genes), while the 
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striatum and cerebellum have the fewest age-related changes 
in gene expression (with only 100+ differential genes). Al-
though these gene expression patterns differ somewhat from 
those detected in the human brain, they nevertheless were 
consistent with the idea of heterogeneity in brain aging 
across different regions, and with the notion that certain re-
gions, such as the cerebellum, exhibit the lowest levels of 
change in gene expression related to the aging process. 
Therefore, patterns of gene expression in other species be-
sides humans may provide additional information about spe-
cific molecular changes that are related to the vulnerability 
of some cells to the aging process, even though the specific 
genes affected by aging may differ among animal species.  
 Functional categorization of aging-associated gene ex-
pression changes in rodent brain indicated that all regions 
show decreases in the expression of genes related to mito-
chondrial function with the decreases being more significant 
in the cerebral cortex, hippocampus, and spinal cord [42]. 
The transcriptomic data also match fairly well with the ob-
served pattern of decreases with age in mitochondrial meta-
bolic capacity of small to medium-sized mitochondria in 
human cerebellum [43]. The mitochondrial metabolic capac-
ity decreases from young to middle age but stays stable from 
middle to old age. The transcriptomic studies in mice and the 
mitochondrial metabolism studies in human cerebellum 
might indicate that this region of the brain is relatively plas-
tic with respect to regulation of gene transcription and me-
tabolism before middle age but becomes relatively insensi-
tive, transcriptionally and metabolically, to the aging process 
after middle age. The differential response of cerebellar neu-
rons at middle age and old age might be due to the lower 
metabolic rate of cerebellar neurons as has been observed for 
both human and primate brains [44-46]. An associated effect 
derived from the low levels of mitochondrial metabolic ac-
tivity in aging cerebellum would be a lowering of the levels 
of reactive oxygen species (ROS) and OS, as well as of DNA 
oxidative damage that results from elevations in ROS levels 
in neurons [47, 48]. Decreased levels of oxidatively modified 
DNA would protect cerebellar neurons from damage that 
might otherwise occur in this brain region. Thus, the study of 
gene expression patterns in animal and human brain during 
aging has enhanced our understanding of the changes that 
occur at the genomic level and which might identify the mo-
lecular causes for the age-associated structural, physiological 
and biochemical changes.  
3. SELECTIVE NEURONAL VULNERABILITY IN 
ALZHEIMER’S DISEASE 
3.1. Brain Regions that are Vulnerable to Alzheimer’s 
Disease 
 AD is characterized by the accumulation of oligomeric or 
aggregated amyloid  peptides (A ) in senile plaques (SPs), 
fibrils of hyperphosphorylated tau protein in neurofibrillary 
tangles (NFTs), and more importantly, by the loss or injury 
of neurons in select brain regions [49]. The cerebral cortex, 
especially the association areas, and the hippocampus, are 
the predominant regions of AD pathology [4, 50, 51]. 
Among these regions, the most vulnerable neurons are those 
in layer II of the entorhinal cortex, the subiculum, and the 
CA1 region of the hippocampus; these neuronal populations 
consistently display high levels of neurofibrillary tangles 
(NFTs) and are first lost in the early phases of the disease 
[52-54]. With regard to the distribution of NFTs across the 
different regions of the cerebral cortex, neurons of the tem-
poral cortex contain more NFTs than those (in decreasing 
order) of the frontal, parietal, occipital, and posterior cingu-
late cortex [55, 56]. Besides the neurons in the cerebral cor-
tex and the hippocampus, many subcortical structures that 
have connections to the cerebral cortex also contain neurons 
with large amounts of NFTs, including the amygdala, nu-
cleus basalis of Meynert, ventral tegmental area, dorsal ra-
phe, locus coeruleus, olfactory bulb, and some midline tha-
lamic and hypothalamic nuclei [57, 58]. In contrast to neu-
rons in these regions that contain high levels of NFT’s, pri-
mary sensory and motor neurons are largely spared in the 
disease [59, 60].  
 Among the most vulnerable neurons in AD are the large 
pyramidal neurons in the areas mentioned above, particularly 
association neurons with long projections [61, 62]. Examples 
of such neurons are those in the entorhinal cortex layer II 
which provide the major cortical input to the hippocampus 
through the perforant pathway, and those in the subiculum 
which represent the major output of the hippocampus to the 
prefrontal cortex and other brain regions [63]. The underly-
ing factors for the vulnerability of these large-sized neurons 
are thought to be their high demand for energy that leads to 
high levels of oxidative phosphorylation. Oxidative phos-
phorylation depends on the activity of the electron transport 
chain (ETC) enzymes, and hyperactivation of these enzymes 
is known to lead to OS and may thus bring about protein, 
DNA, and lipid modifications that are injurious to these neu-
rons. In addition, the relatively large surface area of these 
neurons may increase exposure to extracellular toxic agents 
while their long processes would put increased demands on 
axoplasmic transport over long distances. Finally, neurons 
with long processes also have high levels of neurofilaments 
whose protein subunits tend to form aggregates during cellu-
lar stress. 
3.2. Functional Genomic Studies on Selective Neuronal 
Vulnerability in Alzheimer’s Disease 
 Several investigators have explored the mechanisms of 
region-specific neurodegeneration in AD by performing 
functional genomic studies on the most vulnerable brain re-
gions affected by the disease. A list of these studies (up to 
October 2010) is presented in Table 1 for human subjects 
and Table 2 for animal models of AD. The studies summa-
rized in those two tables vary in their experimental ap-
proaches and include transcriptomic studies of individual 
regions of the brain as well as cross-sectional studies com-
paring regions that exhibit differential neuronal vulnerabili-
ties. As will be noted, some of the studies are based on an 
analysis of gene expression patterns in a whole brain region, 
whereas others represent high-resolution analyses of gene 
expression patterns in individual neurons within a given re-
gion. Despite these different experimental approaches, sev-
eral common patterns are apparent, and these commonalities 
provide some mechanistic insights into the question why 
only certain regions of the brain or certain neuronal popula-
tions are most vulnerable in AD.  
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Table 1. Transcriptomic Studies and Gene Categories that Characterize Selectively Vulnerable Regions in Human AD Brains 
Sample source Technology Gene categories with altered expression in AD Refs. 
I. Region-to-region comparative studies 
Amygdala and cingulate cortex (vulnerable) vs. striatum and cerebellum (resistant) 
6 AD brains (83.0±2.6 [mean±SD] yrs; 
3Female+3Male; CERAD* diagn.), 9 controls 
(65.9±13.5 yrs; 2F+7M) 
Unigene Lifearray 
microarrays (InCyte) 
Up-regulation of chronic inflammation and down-regulation of 
signal transduction and energy metabolism in vulnerable regions 
[85] 
Entorhinal cortex (vulnerable) vs. dentate gyrus (resistant)  
6 AD brains, 6 controls  
(Information not available) 
GeneChip Human 
Genome HG-U133A  
VPS35 and retromer complex  [132] 
Entorhinal cortex (EC), hippocampus (HIP), middle temporal gyrus (MTG), and posterior cingulate cortex (PCC) (vulnerable) vs. superior frontal gyrus 
(SFG) and primary visual cortex (VCX) (resistant) 
33 AD brains (79.9±6.9 yrs; 18F+15M; Braak III-
VI), 14 controls (79.8±9.1 yrs; 4F+10M) (neurons 
obtained by LCM) 
GeneChip Human 
Genome U133 Plus 2.0 
Synaptic transmission and synaptic vesicle transport down-
regulated in EC and HIP. Microtubule-based movement and axon 
cargo transport decreased in MTG and PCC. Energy metabolism 




Hippocampus (vulnerable) vs. parietal cortex (resistant)  
4 AD brains (81.5±7.1 yrs; 1F+3M; Braak III), 4 
controls (87.8±4.7 yrs; 3F+1M; Braak I-II) 
UniGem V array (In-
cyte) 
Calcineurin A  up-regulated in vulnerable region [123] 
II. Single vulnerable region  
Cerebral cortex  
Frontal cortex  
61 AD brains (78.0 yrs [mean]; 31F+30M), 23 
controls (73.0 yrs, no gender information) 
Two custom cDNA 
microarrays 
Calcium dysregulation in AD [73] 
6 AD brains (85±7 yrs), 6 controls (74±10 yrs) Atlas human 12K 
microarray (Clontech) 
Increased production of interferon-  and up-regulation of inter-
feron-induced genes in AD brain 
[94] 
13 AD brains (82.8±6.2 yrs; 10F+3M), 11 con-
trols (75.8±10.5 yrs; 5F+6M) 
Affymetrix HuFL 
GeneChips 
Down-regulation of synaptic vesicle trafficking in AD brains [112] 
Inferior parietal lobe  
10 AD (82.3±6.7 yrs; 4F+6M; Braak V-VI), 6 
demented but non-AD (70.7±9.0 yrs; 2F+4M), 10 




Immune response, CNS development, and A  processing and 
disposition were among the most changed in AD brains 
[96] 
Superior temporal gyrus  
8 AD brains (72.6±9.1 yrs; 3F+5M; Braak V/VI 
(except 2 III/IV), 8 controls (80.1±7.1 yrs; 
3F+5M; Braak 0-II (except 1 III/IV)) 
GeneChip Human 
Exon 1.0 ST Arrays 
Synaptic dysfunction, perturbed neurotransmission, and activation 
of neuroinflammation in AD brains 
[98] 
5 AD brains (moderate dementia; CDR** 2), 6 
controls (CDR 0) 
UniGem V1 array 
(Incyte) 
Synaptic vesicle protein synapsin a-type isoform selectively de-
creased in vulnerable regions of AD brains 
[111] 
Hippocampus  
Whole hippocampus  
2 AD brains (80,82 yrs; both M), 3 controls 
(58,68,78 yrs; all M) 
GeneChip Human 
Genome HG-U133A  
Genes related to energy metabolism were down-regulated in the 
AD-affected region 
[88] 
AD brains (83.2±8.1 yrs; 10F+8M; CDR 3-5) and 
controls (78.5±14.7 yrs; 6F+5M; CDR 0) 
Genome-wide cDNA 
array 
Impaired glucose/energy metabolism and attenuation of PGC-1  
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(Table 1). Contd….. 
Sample source Technology Gene categories with altered expression in AD Refs. 
Hippocampal CA1  
22 AD brains (7 Incipient: 90.0±5.6 yrs, 
MMSE*** 20-26; 8 moderate: 83.4±3.1 yrs, 
MMSE 14-19; 7 severe: 84.0±10.6 yrs, 
MMSE<14), 9 controls (85.3±8.1 yrs; MMSE>25) 
GeneChip Human 
Genome HG-U133A  
Up-regulation of tumor suppressors, oligodendrocyte growth 
factors, protein kinase A modulators, cell adhesion, apoptosis, 
lipid metabolism, and inflammation; down-regulation of protein 
folding/metabolism/transport, energy metabolism and signaling in 
AD brains 
[90] 
6 AD brains (70.3±3.3 yrs; 3F+3M; CDR 2-3), 6 
controls (69.0±1.8 yrs; 3F+3M; CDR 0) 
GeneChip Human 
Genome U95Av2  
Dysregulation of metal ion homeostasis; down-regulation of 
transcription factor signaling and neurotrophic support; upregula-
tion of apoptotic and neuroinflammatory signaling in AD 
[97] 
5 AD brains (77.2±7.4 yrs; 2F+3M), 5 controls 
(73.2±9.8 yrs; 2F+3M) (CA1 neurons obtained by 
LCM) 
Incyte GDA array and 
custom cDNA array 
CA1 neurons with neurofibrillary tangles have significant reduc-
tions in phosphatases/kinases, cytoskeletal proteins, synaptic 
proteins, glutamate receptors, and dopamine receptors in AD 
[70] 
Nucleus basalis of Meynert  
10 AD brains (84.5±4.0 yrs; 7F+3M; MMSE 
14.8±8.6), 6 controls (81.5±7.2 yrs; 4F+2M; 
MMSE 27.4±1.5) (cholinergic neurons collected 
by single-cell aspiration) 
Custom cDNA arrays Neurotrophin receptors, synaptic proteins and protein phospha-
tases down-regulated in AD brain 
[113] 
*CERAD: Consortium to Establish a Registry for Alzheimer's Disease; **CDR: clinical demention rating; ***MMSE: Mini-Mental State Examination. 
 
Table 2. Transcriptomic Studies that Characterize Selective Vulnerability in Brains from Mouse Models of AD 
Sample source Technology Gene categories with altered expression in AD Refs. 
I. Region-to-region comparisons 
Hippocampus and cortex (vulnerable) vs. cerebellum, striatum and brainstem (resistant) 
 4 APP+PS1 transgenic, 4 non- 
 transgenic controls (17-18 mos  
 littermates) 
Rat LifeArray 1 & 2  
(InCyte) 
Down-regulated memory consolidation and up-regulated in-
flammatory genes in transgenic mice 
 [93] 
II. Single vulnerable region 
Cerebral cortex  
Whole cerebral cortex  
10 Balb/c with icv inj. of aggregated A 25-35, 
10 with saline (weight 22-24 g) 
Atlas Mouse 1.2 Expres-
sion Array 
Apoptosis, energy metabolism, calcium ion homeostasis dys-
function, cell adhesion and neuronal dystrophy in A -treated 
mice 
[86] 
3 AD model genotypes: APP/PS-1P264L/P264L(4 & 
18 mos, n=3 each age), Tg2576/PS-1P264L/P264L & 
Tg2576/PS-1P264L/+(2 & 12 mos, n=3 each 
age/genotype) and wild-type mice (n=3 corre-
sponding to each genotype) 
GeneChip Murine Ge-
nome U74A 
Up-regulated in the 3 AD models: immune response, carbohy-
drate metabolism, and proteolysis. Down-regulated: pituitary 
adenylate cyclase-activating peptide (PACAP), brain-derived 
neurotrophic factor (BDNF), and insulin-like growth factor I 
receptor (IGF-IR) 
[87] 
Frontal cortex  
15 PS1/PS2 double knockout mice and 15  
wild-type controls (2, 4, 6, 7 & 8 mos; 3 ani-
mals pooled at each age) 
GeneChip Mouse Ge-
nome 430 
Progressive, age-dependent up-regulation of neuroinflammation 
and cathepsin in transgenic mice 
[95] 
Hippocampus  
Whole hippocampus  
5 APPsw transgenic mouse brains, 5 non-
transgenic controls (12 mos littermates) 
ABI mouse genome 
survey array 
Up-regulated: signal transduction and protein binding; down-
regulated: extracellular space, protein binding, cell communica-
tion, and transporter activity in transgenic mice 
[124] 
15 PS1/PS2 double knockout mice and 15  
wild-type controls (2, 4, 6, 7 & 8 mos; 3 ani-
mals pooled at each age) 
GeneChip Mouse Ge-
nome 430 
Progressive, age-dependent up-regulation of neuroinflammation 
and cathepsin in transgenic mice 
[95] 
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3.2.1. Gene Expression Patterns in Different Brain Regions 
in AD 
 The region-specific studies cover most brain areas af-
fected by AD, including the entorhinal cortex, hippocampus, 
temporal cortex, frontal cortex, parietal cortex, cingulate 
cortex, amygdala, and nucleus basalis of Meynert. Because 
of their significance in cognition and memory formation, 
gene expression patterns in the hippocampus and frontal cor-
tex have been examined in several of these studies. An effec-
tive approach to study SNV in AD is to compare vulnerable 
regions with resistant regions. As listed on the top of Table 
1, a number of vulnerable vs. resistant regional comparisons 
were conducted, covering the majority of the vulnerable re-
gions listed above. Regions of the brain populated with neu-
rons that are resistant to AD-related damage included the 
striatum, visual cortex, cerebellum, and brainstem. However, 
many of the existing genomic expression studies shown in 
Table 1 were not direct, side-by-side comparisons of the pat-
terns of gene expression in vulnerable vs. resistant regions. 
For many of these studies, only vulnerable regions were used 
and the corresponding analyses were focused on how the 
patterns observed in these vulnerable regions differed be-
tween brains from AD subjects and those from age-matched 
controls. Although the majority of the gene analyses were 
carried out with RNA isolated from dissected brain regions, 
those described in references 46 and 47 were done with RNA 
isolated from cells selected by LCM. 
3.2.2. Methodological Considerations with Regard to Gene 
Expression Studies in AD 
 It is well known that within a brain region characterized 
by overall sensitivity to stress there are cells that are resistant 
to the stress stimuli. A good example of this is the high level 
of sensitivity to OS, ischemia-induced injury, or glutamate 
toxicity of pyramidal neurons in the CA1 subfield of the hip-
pocampus whereas the proximal neurons in the CA3 subfield 
are resistant to the same adverse conditions [64-67]. With 
regard to AD-associated neuronal injury or loss, the hippo-
campus as a whole is usually considered as a vulnerable re-
gion but the CA1 pyramidal neurons are much more suscep-
tible to the pathogenic condition in AD than are neurons in 
the CA3 subfield or in the dentate gyrus [8]. Therefore, stud-
ies of brain metabolism and or gene expression that examine 
regional brain differences are actually reporting on the aver-
age metabolic or transcriptomic activity of a region that is 
composed of both sensitive and resistant neurons.  
 Although it is ideal to conduct studies on SNV using only 
vulnerable neurons rather than all of the cells in a given re-
gion, the technical difficulties involved in collecting individ-
ual neurons still poses a considerable challenge to investiga-
tors. For this reason, most published genomic expression 
studies of SNV in AD are studies of whole brain regions. In 
such studies, unique markers of vulnerable neurons might be 
masked by signals from stress-resistant neurons, and differ-
ences between vulnerable and resistant neurons can be di-
luted by background noise from other cells in a given brain 
region, such as glial cells. But, at the single cell level, the 
ratio of genuine signals to false signals or background noise 
is much greater making the results more dependable. Recent 
developments in selective cell procurement technologies, 
such as LCM, have made high-resolution analyses a reality 
[68]. The low mRNA yield that accompanies the usually 
small number of cells captured by LCM can be remedied by 
linear amplification of the messenger molecules [69]. As 
shown in Table 1, among existing studies, several groups 
employed the target cell capture approach and demonstrated 
the feasibility and power of gene expression analysis per-
formed on a uniform population of cells [70-72].  
 The vast majority of functional genomic studies related 
to regional vulnerability in AD have used postmortem brain 
tissue from human AD subjects and the respective age-
matched controls (Table 1). In most of these studies, fewer 
than 10 human brains per group were analyzed. The largest 
population of AD cases reported thus far involved analysis 
of samples from 61 AD patients [73]. In this review, we have 
also examined the patterns of gene expression in experimen-
tal animals that are used as surrogates of human AD so that 
we may determine whether animals thought to represent 
models of AD exhibit similar patterns in terms of selectively 
vulnerable or resistant neuronal populations as do humans. 
The animal models used are, for the most part, transgenic 
mice that over-express one to three genes associated with 
familial cases of AD. These are the transgenic mice for amy-
loid precursor protein with Swedish mutation (APPsw) and 
those with APP plus presenilin 1 (PS1), as well as the double 
gene knockout mice for PS1 plus PS2. In addition, brain tis-
sue from wild type mice injected with -amyloid has been 
analyzed in order to determine the gene expression patterns 
in vulnerable vs. resistant neuronal populations. The findings 
from these animal studies are summarized in Table 2 and the 
observed gene expression patterns integrated into the overall 
pattern of SNV in AD.  
 Early transcriptomic studies of AD-vulnerable regions 
focused mainly on the identification of differentially ex-
pressed genes that investigators believed to be important for 
the disease process. Although attention to single gene 
changes may provide valuable information about potential 
targets for therapeutic intervention in AD, such an approach 
does not allow for the visualization of possible gene interac-
tions and the effect that such interactions may have on dis-
ease-relevant molecular pathways in cells. To achieve an 
understanding of the disease process, a “systems approach” 
to analyzing transcriptomic data should provide a more com-
prehensive view of the disease process [74] and would, 
therefore, be the preferable approach for data analysis in 
such studies. Bioinformatic analyses of transcriptomic data 
now encompass the identification of genes, gene ontologies, 
bio-functions, biological pathways, and gene networks. More 
recent studies of SNV in AD brains have made use of gene 
ontological annotations, expert annotated and compiled bio-
functions (such as those offered by Ingenuity Systems), and 
the currently known biological pathways, in order to identify 
key gene ontologies, bio-functions and pathways that can 
differentiate vulnerable from resistant neurons in AD. These 
higher-level analyses have provided more insight into the 
underlying mechanisms of SNV in AD than the early studies 
did.  
3.2.3. Possible Common Mechanistic Factors Determining 
Neuronal Vulnerability in AD 
 It is usually not easy to determine whether the findings 
from a single transcriptomic study can be used in deriving 
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general principles about the state of neuronal injury in the 
brain. Added to this uncertainty are possibly confounding 
experimental parameters such as brain region, cellular reso-
lution, brain tissue origin, and others already mentioned 
above. In an effort to reach the goal of understanding the key 
mechanistic factors underlying SNV in AD, we have col-
lected data from existing studies and have attempted to de-
termine if there are common mechanistic factors that have 
been identified by many of the studies we have examined. 
Shared key bio-functions and pathways identified in the 
studies we have summarized were used to arrive at possible 
mechanisms for differential vulnerability of neurons in AD. 
The factors we have identified represent the most prominent 
characteristics of AD-affected regions and are factors that 
were reproducibly observed in many studies, despite the use 
of different regions or diverse neuronal populations from the 
brains of either human subjects or animal models. The key 
biological functions and molecular pathways that seem to 
distinguish vulnerable from resistant neurons in AD are out-
lined below, and some of the key genes in these functions are 
presented in Table 3. 
a. Decreases in Mitochondrial Metabolism and Energy 
Production 
 Since the metabolic activity of the brain is very high, 
accounting for an estimated 20-25% of glucose and oxygen 
utilization in the body, it is not surprising that reduced me-
tabolism and energy production might be significantly corre-
lated with cognitive decline in AD [75, 76]. The CMRGl is 
significantly lower in AD-affected brain regions when com-
pared with the same brain regions of age-matched healthy 
controls [77-80]. On the other hand, the same measurements 
of the metabolic rate in regions spared by the disease process 
are equivalent to those in the brains of control subjects. De-
creases in CMRGl in AD have been reported for regions that 
are most vulnerable as defined by neuropathological 
changes, including those of the frontal, parietal, temporal, 
and posterior cingulate cortex, as well as the hippocampus 
and entorhinal cortex [80-82]. It is also highly significant 
that the regions that tend to accumulate the highest amounts 
of A  in AD, or in cognitively normal individuals with amy-
loid plaques in their brain, differ from other brain regions in 
terms of the overall levels of glycolytic activity [83, 84]. 
Glucose metabolism in brain is generally through the path-
way that includes oxidative phosphorylation in mitochondria 
but, apparently, in the most vulnerable regions of the brain, 
glucose metabolism is through the glycolytic pathway, a 
pathway that leads to more rapid utilization of glucose but 
less ATP generation. Thus, differences in energy metabolism 
and glucose utilization in brain are emerging as prominent 
features of an AD brain as compared with non-AD brains. 
As shown in Tables 1 and 2, the down-regulation of genes 
related to metabolic homeostasis and energy production is a 
recurring theme in AD brains [71, 72, 85-90]. For example, 
Liang et al. [72] compared expression of 80 metabolically 
relevant genes in brain regions differentially affected by AD. 
Compared with controls, vulnerable regions in brains of AD 
cases exhibited significant decreases in the expression of 
many genes related to cellular metabolism. In the posterior 
cingulate cortex, 70% of the nuclear genes that encode mito-
chondrial ETC subunits were expressed at significantly 
lower levels in the AD cases compared with controls. In 
middle temporal gyrus and hippocampal CA1 subfield, ex-
pression levels of 61% to 65% of these genes were signifi-
cantly lower in AD brains vs. those in age-matched controls. 
In comparison, in a region that is relatively spared by AD, 
i.e., the visual cortex, only 16% of the genes were expressed 
at lower levels than in controls. This detailed study, along 
with many others, demonstrates that there is a decline in mi-
tochondrial energy metabolism in the AD brain, and that the 
regions that suffer the greatest decline in genes related to cell 
metabolism and energy production are those that are most 
vulnerable to the disease process in AD. Among the mito-
chondrial ETC proteins whose genes are down-regulated in 
AD, the genes Cox4 (Cytochrome c oxidase, subunit IV) and 
Uqcrc2 (Cytochrome bc-1 complex core protein) are the 
most consistently down-regulated genes. It is important to 
point out that in addition to the lower expression levels of 
genes related to ETC enzymes in vulnerable neurons in the 
AD brain, those for subunits of the translocases of the outer 
and inner mitochondrial membranes (Tomm and Timm) are 
also down-regulated in these regions [91]. These translocases 
play an important role in the import of mitochondria-targeted 
proteins from the cytoplasm through the outer and inner mi-
tochondrial membrane. Included in the group of proteins 
transported into mitochondria are many of the ETC enzymes. 
To add to the importance of TOMM proteins in AD, new 
polymorphisms associated with AD (multiple T bases) have 
now been identified in an intron of the gene for one of the 
subunits of the TOMM complex, Tomm40 [92]. This genetic 
variation leads to the development of late onset AD at an 
earlier age than most such cases of late onset AD. 
b. Increases in Gene Expression of Inflammatory Response 
Genes 
 In many of the studies listed in Table 1 [85, 87, 90, 93-
98], inflammatory responses are among the most pronounced 
bio-functions or pathways associated with up-regulated 
genes in affected AD neurons. A  aggregation and deposi-
tion in AD brains is known to be neurotoxic and to elicit the 
production of cytokines, chemokines, and other neuroin-
flammatory mediators from microglia, the immune system 
cells of the brain [99, 100]. Up-regulated genes involved in 
this response, as uncovered by functional genomic studies, 
include those for: 1) cytokines (such as interleukin[IL]-1 , 
IL-1 , IL1F7, interferon 5, interferon , interferon 2, 
transforming growth factors 1 and 3, and tumor necrosis 
factor ); 2) chemokines (such as CCL5 and CCL27); 3) 
cytokine/chemokine receptors (such as chemokine C-X-C 
motif receptor 2 [CXCR2], CXCR4, CCR3, IL-1 receptor 
type I, IL-2 receptor , IL-10 receptor , IL-10 receptor , 
IL-13 receptor 1, and receptors of IL-6, IL-17, and IL-18); 
4) proinflammatory transcription factors (such as NF-IL6 
and NF- B 2) and other pro-inflammatory proteins (such as 
interferon-induced protein 3 or IFITM3). Not all of these up-
regulated genes (or their products) are pro-inflammatory, of 
course, since some of the gene products, such as those of the 
IL-10 receptor, are anti-inflammatory [101]. Overall, these 
findings are consistent with other experimental evidence 
showing that in AD brains, inflammation is particularly lo-
calized in regions most affected by the disease [102-109]. 
The up-regulation of some anti-inflammatory genes may be 
indicative of a compensatory response to inflammation in 
AD brains. Based on the fact that increased expression of 
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inflammatory response genes is primarily focused on the 
AD-vulnerable regions, it is highly likely that neuroinflam-
mation is a significant contributor to the pathogenic cascade 
that is activated in AD [110]. Although the activation of in-
flammatory responses in AD-affected regions might be neu-
roprotective at the early stage of the disease by controlling 
and minimizing the damaging effects of A , chronic 
inflammation and long exposure to inflammatory response 
effectors might well be detrimental to neurons and glial cells 
in later stages of the disease.  
c. Dysfunction of Synaptic Transmission and Synaptic 
Vesicle Transport 
 The third common transcriptional profile identified in 
many of the studies is the alteration in levels of gene expres-
sion related to synaptic activity in vulnerable neurons [70-
72, 98, 111-113]. Since synaptic activity is fundamental to 
memory formation and cognitive function, the region-
specific decreases in gene expression related to synaptic neu-
rotransmission uncovered in these studies can be viewed as a 
neurobiological correlate of AD-associated cognitive de-
cline. Specifically, these studies demonstrate that the expres-
sion of many important genes for synaptic transmission or 
vesicular transport are significantly down-regulated, includ-
ing the genes for neuritin, synapsin I, synapsin II, synapto-
brevin, synaptojanin, synaptophysin, synaptopodin, synapto-
tagmin, syntaxin, -synuclein, and -synuclein. The down-
regulation in sensitive regions of genes related to synaptic 
vesicle docking and recycling at the synapse, such as dy-
namin I, is also likely to be linked to the decline in cognitive 
function in AD, because of the ensuing decreases in neuro-
transmitter release at synapses. This observation suggests a 
selective weakening or loss of neuronal connections in AD-
affected brain regions, and may help explain the decreases in 
synaptic density observed by quantitative morphometric 
analyses performed on brain regions vulnerable to AD-
induced damage [114-116]. Biochemical analyses of these 
protein products are in agreement with the transcriptional 
profile described above [117-119]. Region-specific dysfunc-
tion in synaptic transmission may result not only from the 
down-regulation of the genes described above, but also from 
direct effects of A  on synaptic macromolecules [120, 121], 
or from the effects of products of chronic inflammatory re-
sponse, such as tumor necrosis factor [122], or from other 
factors some of which are discussed below.  
d. Calcium Regulation, Cytoskeletal Function, Signal 
Transduction, and Proteolytic Activity 
 Additional transcriptomic alterations that might also play 
a role in AD-associated SNV were identified in the func-
tional genomic studies. These include: 1) Up-regulation in 
AD-vulnerable regions of genes related to calcium (Ca
2+
) 
homeostasis and signaling pathways, such as the inositol 
trisphosphate (IP3)-receptor kinase and the Ca
2+
-regulated 
phosphatase calcineurin (Ppp3c), as well as the down-
regulation of genes encoding calcium binding proteins [73, 
85, 86, 95, 123]; 2) Down-regulation of the expression of 
genes for cytoskeletal proteins, e.g., -tubulin and neuro-
filament subunits Nf-L, Nf-M, Nf-H and Nf-66, as well as 
those for some axonal cargo transporters in AD brains [70, 
85, 90]; 3) Down-regulation in AD brains of genes involved 

















Fig. (2). Major functional categories of genes whose expression is altered in neurons frequently damaged in AD. Genes in parentheses are 
some of the most representative and those that are most frequently detected as being over- or under-expressed in AD brains in more than one 
study (see Table 3). The genes in boldface type are those for which the respective protein levels have been confirmed as ones that change in 
AD in the same direction as the gene expression levels. The arrows after each gene represent the direction of their respective change in vul-
nerable regions during AD pathogenesis. Some of the major gene expression patterns characteristic of vulnerable neurons in AD are also 
shared by neurons that are susceptible to the effects of the aging process, as well as neurons sensitive to the damaging effects of oxidative 
stress (see text).  
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Table 3. Functionally Categorized Key Genes Identified in Transcriptomic Studies as Being Characteristic of Vulnerable Regions 
in Human AD or Animal Models of AD (Underlined: Down-Regulated Genes; Non-Underlined: Up-Regulated Genes) 




Mitochondrial metabolism and energy production 
COX4I1, TPI1, TPI1P1, LMO4, NDUFS5, LOC100130794, LOC652797, PKM2, 
ENO3, UQCRC2, OXCT1, SLC25A4 
FC* > 2.0 nc** Human [85] 
OXPHOS: ATP5A1, ATP5B, ATP5C1, ATP5G3, ATP5O, COX5B, NDUFA1, 
NDUFA10, NDUFA11, NDUFA13, NDUFB8, SDHB, UQCRC1, UQCRC2, etc. 
Mito membrane translocases: TIMM17A, TIMM23, TIMM50, TOMM22, TOMM34  




Glycolysis: GAPD, GPI, LDHA; TCA: ACLY, FH, MDH1, MDH2, SUCLA2; OX-
PHOS: ATP5B,COX4I1, COX6A1, NDUFS4, UQCRC2, SLC25A14 
P < 0.05 nc Human [88] 
Glycolysis: GAPD, GPI, PFKM, PGK1; TCA: ACLY, CS; OXPHOS: COX6C, 
MTATP6; Pyruvate metabolism: PC, PCK2, PDHA1, PDK3; Others: PPARGC1A 
(PGC-1 ), UCP2 




ACAD8, ALDH2, COX7A2L, COX7C, HADH, NDUFB3, PDHA1, PDHX, 
SDHA,SLC25A6 
P < 0.05 (FDR) nc Human [90] 
Carbohydrate metabolism: FUCA1, GUSB, MAN2B1  nc Mouse [87] 
Neuroinflammatory response 
C3, HLA-DRB5, CD74, CD99 FC > 2.0 nc Human [85] 
IFITM3 FC > 5.0 nc Human [94] 
CCL5, C4A, IL1F7, IL1R1, NFKB2, TGFB1, TGFB3, TNFSF7 FDR  10%  Human [98] 
CCL27, CCR3, CCR5, CXCR2 (IL-8R ), CXCR4, IL-28A 
P < 0.02 (Permuta-
tion)  
CCR3, CXCR4 Human [96] 
IFNA5, IFNG, IL10RA, IL10RB, IL13RA1, IL17R, IL18, IL2RG, IL6R P < 0.05 (FDR) nc Human [90] 
APP, B94, CEX1, DPP1, HB15, HUMJE, IFNIND, IL1A (IL-1 ), IL1B (IL-1 ), NF-
IL6, NFKBIA, PLA2G4A, PTGS2, RELB 
FC  3.0& P  0.05 nc Human [97] 
C1QA, C1QB, C4A, CBS, THRA, GFAP FC > 1.4& P < 0.05 nc Mouse [93] 
AKT1, CSF2RB2, GPI1 FC  2.0 nc Mouse [86] 
C1QA, C4A, CD14, FCGR1, GFAP, IGH-6 FC  1.2& P  0.05 nc Mouse [87] 
C1QA, C1QB, C1QC, C3AR1, C4B FC > 2.0& P < 0.05 C1QA Mouse [95] 
Synaptic transmission and synaptic vesicle transport 
CHRNB2, DRD1IP, GABRA1, GABRA4, GABRG2, GAD1, GAD2, GRIA2, 
GRIA3, GRIA4, GRIK1, GRIK4, GRINA, GRIN2A, GRIN2D, GRM4, HTR1B, 
HTR2A, HTR3B, NRN1, SNAP25, STX12, SV2A, SV2B, SYNJ1, SYT8, SYT11, 
SYT12, SYT13, VAMP1 
FDR  10% GAD65 (GAD2) Human [98] 
DNM1, STX1A, SYT1  P < 0.05 DNM1 Human [112] 
SYN2(a) FC  1.8 
Synapsin Ia, IIa, 
IIIa 
Human [111] 
CHAT, CSPG5, NFL, SLIT2, SYN1, SYP FC  3.0& P  0.05 nc Human [97] 
ARC, SLC6A3 (DAT), DRD1, DRD2, DRD3, DRD4, DRD5, GRIA1, GRIA2, 
GRIN2B, SYN1, SYP, SNCA, SNCB, SYTx 
FC  2.0 nc Human [70] 
SYP, SYTx P  0.05 nc Human [113] 
ARC, ATP1A3, EGR1 (Zif268), NR4A1 (Nur77/TR3) FC > 1.4& P < 0.05 nc Mouse [93] 
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PPP3CB (Calcineurin A ) FC>2.0 nc Human [123] 
ITPKB, RGS4 P < 0.05 nc Human [73] 
CAST, DAPK2, EP300, S100A4 P < 0.05 (FDR) nc Human [90] 
Cytoskeletal function 
VPS35 P < 0.01 VPS35 Human [132] 
NF-L, NF-M, NF-H, TUBB FC  2.0 nc Human [70] 
Signal transduction 
AHNAK, CHL1, COPS8, ENSA, FKBP4, GSK3A, ITPR1, MAPK10, MAP2K1, 
MAP3K6, NOMO3,NOMO1,NOMO2, NPTN, NR4A1, PGRMC1, PIP4K2B, 
PPAP2C, PPP2CA, PRKACB, PRKCZ, PTK2, RAN, RCAN2, RGS5, RUNDC3A, 
SIRPA,YWHAB 
FC > 2.0 nc Human [85] 
AIM1, CDK2AP1, FZR1, GSK3B, SFRP1, TGFBR3 P < 0.05 (FDR) nc Human [90] 
AKT3, CDK5, GNA12, GNB5, GNG5, GSK3B, MAPK4, MAPK6, MAPK8, 
MAPK9, PLCB2, PPP3CB, PPP2R1B, PRKCB1, PRKCD, PRKCE, PRKCZ, RGS4 
FDR  10% AKT3, GSK3  Human [98] 
ADAM9, CDP5, DAXX, FAS  FC  3.0& P  0.05 nc Human [97] 
ERK1, ERK2, FAK, GSK3B, NOS2, PPP1CA, PPP1CC, PPP2R1A, PPP2CA FC  2.0 nc Human [70] 
PPP1CA, PPP1CC P  0.05 nc Human [113] 
AKT1, CDH2, ERBB2, FGFR1, FZD3, FZD7, ITGAL, ITGAM, JUN, LIMK1 FC  2.0 ITGAM Mouse [86] 
ADORA2A, ATP2A1, BMP2, CACNG8, CAMTA2, CAP1, CIDEA, DUSP9, GAL, 
GNG8, GPR27, GPR77, GPR151, HCN2, KCNA5, MAP3K8, OXT, PDE6G, 
PLA1A, PRKAG3, RBL1, S100A8, SHC1, SMAD4  
FC  2.0& P < 0.05 nc Mouse [124] 
Protein folding and proteolytic activity 
AHSA1, CCT2, CCT3,CCT4, CCT5, DNAJA1, HSP90AB1, HSP90AA2, 
HSP90AA1, PDIA6 
P < 0.05 (FDR) nc Human [90] 
CTSD FC  2.0 nc Human [70] 
CTSD P  0.05 nc Human [113] 
CTSD, CTSH, CTSS FC  1.2& P  0.05 nc Mouse [87] 
CTSC, CTSD, CTSH, CTSS, CTSZ  FC > 2.0& P < 0.05 CTSD Mouse [95] 
Neurotrophic support 
BDNF, HER2B, P2XR  FC  3.0& P  0.05 nc Human [97] 
NTRK2 (trkB), NTRK3 (trkC) P  0.05 nc Human [113] 
ADCYAP1 (PACAP), BDNF, IGF1R FC  1.2& P  0.05 nc Mouse [87] 
*FC: Fold Change; **nc: no confirmation; ***FDR: Benjamini and Hochberg False Discovery Rate. 
receptor (GPCR) signaling [85, 90, 124]; 4) Down-
regulation of genes for neurotrophic factors and their recep-
tors, such as Bdnf (brain-derived neurotrophic factor) and the 
receptors TrkB and TrkC [87, 97, 113]; and 5) Up-regulation 
of the genes for cathepsin D, H, S and Y, a family of 
endolysosomal proteases involved in the proteolytic cleavage 
of APP and the formation of A  [70, 87, 93, 95, 113].  
4. CONCLUDING REMARKS 
 In the preceding sections we have presented information 
from microanatomical, brain imaging, functional imaging, 
and functional genomic studies in order to begin to define 
the intrinsic characteristics of selectively vulnerable neurons 
in the aging brain and in AD. Potential candidate neuro-
chemical processes have been suggested in the past as possi-
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ble determinants of differential vulnerability, especially the 
expression of high levels of neurofilament proteins in vul-
nerable neurons and of calcium-binding proteins in resistant 
neurons [6]. However, the information gleaned from those 
studies, although accurate, was relatively limited when com-
pared with the large data sets available to us today as a result 
of whole genome expression studies. The key functional 
gene categories that have emerged from our review of stud-
ies that distinguish vulnerable from resistant neurons are 
summarized in Fig. (2). The summary shown in Fig. (2) 
highlights what appear to be intrinsic differences between 
vulnerable and resistant neurons in terms of gene expression, 
regardless of the site of their location in brain.  
 The summary of studies at the genomic level presented in 
this review, points to some commonalities between aging 
and AD, the primary ones being the decline in energy me-
tabolism, the altered Ca
2+
 homeostasis and signaling, the 
decreases in synaptic neurotransmission, and the enhanced 
inflammatory responses. The genomic differences between 
vulnerable and resistant neurons fit quite well the hypotheti-
cal schemes already developed in the literature to account for 
the neuronal losses observed in aging and AD brains, i.e., the 
mitochondrial cascade hypothesis [125], the Ca
2+
 hypothesis 
of aging and AD [126, 127], the synaptic disruption hy-
pothesis of AD and aging [128, 129], and the neuro-
inflammation hypothesis of aging and AD [130].  
 Several of the functional categories of genes shown in 
Fig. (2), are also differentially expressed in neurons that are 
vulnerable to OS, regardless of their location in the brain 
[65, 66]. Included among these categories are those of en-
hanced immune/inflammatory response, decreased energy 
generation, reduced signal transduction, and dysregulation of 
Ca
2+
 signaling. The oxidative stress hypothesis of aging is 
one of the predominant theories of age-associated cell dam-
age and death in many organs, including the brain [131]. 
Thus, the functional genomics approach to defining some of 
the molecular characteristics of neuronal vulnerability to 
aging and AD has confirmed most of the major hypotheses 
of molecular and cellular changes proposed as key processes 
leading to neurodegeneration in aging and AD. What the 
summary of the functional genomic studies of brain in aging 
and AD have offered beyond the identification of potential 
pathways to neuronal vulnerability are key genes and gene 
products related to these pathways and whose expression is 
intrinsically different in vulnerable vs. resistant neurons. The 
identification of specific genes in these pathways that may 
determine vulnerability of neurons can be used for future 
drug development to prevent the loss of neurons in neurode-
generative diseases such as AD. For example, the develop-
ment of drugs against specific targets that control calcium 
signaling or against some of the inflammatory response fac-
tors may provide the means to protect selectively vulnerable 
neurons from further damage in AD. Mitochondrial meta-
bolic dysfunction, either because of down-regulation of the 
expression of ETC enzymes or mitochondrial membrane 
translocases, such as TOMM40, may also become an attrac-
tive target for the development of agent that delay the stress 
of the aging process or the initiation and continuation of the 
damage induced in AD-sensitive neuronal populations.  
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